What Has Stem Cell Therapy
Been Studied For?
An honest, plain-English look at where the research stands for different conditions. No hype. No overselling. Just what the science actually says â so you can make an informed decision.
This tool is for educational purposes only and does not constitute medical advice. Research summaries reflect the current published literature on mesenchymal stem cell (MSC) therapy. Always consult a qualified healthcare provider.
Osteoarthritis (OA)
One of the most studied applications. Multiple clinical trials show promise for knee OA in particular.
What the research says
Osteoarthritis â especially knee OA â is the single most-studied condition for mesenchymal stem cell therapy. Dozens of randomized controlled trials (RCTs) and several meta-analyses have been published. The overall picture: many patients report reduced pain and improved function, particularly in mild-to-moderate cases. Some imaging studies have shown signs of cartilage preservation, though complete cartilage regeneration remains debated.
Rheumatoid Arthritis
MSCs are natural immune regulators â a powerful fit for RA. Clinical results are encouraging and the field is advancing quickly.
What the research says
MSCs are uniquely suited for autoimmune conditions because they naturally regulate the immune system â essentially helping calm overactive immune responses rather than just suppressing symptoms. Clinical studies show patients experiencing reduced joint inflammation, improved mobility, and in some cases decreased reliance on immunosuppressive medications. The biological rationale here is especially strong, and the field is moving quickly toward larger confirmatory trials.
Back Pain & Disc Degeneration
Degenerative disc disease is a major research target. Studies show pain reduction and disc hydration improvements.
What the research says
Intervertebral disc degeneration is one of the leading causes of chronic back pain. Several clinical trials have examined intradiscal injection of MSCs and found reductions in pain scores, with some studies showing improved disc hydration on MRI. The challenge: disc environments are harsh (low oxygen, high pressure), which can limit cell survival.
Neck Pain & Cervical Issues
Less studied directly than lumbar, but shares the same degenerative mechanisms. Systemic benefits apply.
What the research says
Most spinal MSC research has focused on the lumbar spine, but cervical disc degeneration shares the same underlying pathology. The anti-inflammatory and tissue-supportive properties of MSCs apply systemically. A handful of studies have specifically examined cervical applications with promising early results, particularly for patients who want to avoid cervical fusion surgery.
Tendon & Ligament Injuries
One of the most exciting areas of MSC research. Pro athletes and weekend warriors alike are seeing results backed by strong clinical data.
What the research says
Tendon and ligament injuries heal slowly because these tissues have limited blood supply â which is exactly why MSC therapy is such a promising solution. Studies on rotator cuff tears, Achilles tendinopathy, tennis elbow, and ACL injuries consistently show improved healing rates, reduced re-tear rates, and faster return to activity. Professional sports has embraced MSC therapy, bringing significant research funding and real-world validation to the field.
Hip Osteoarthritis
Less studied than knee OA but follows similar mechanisms. Early results are positive for pain relief.
What the research says
Hip OA research with MSCs lags behind knee studies but is growing. The available clinical data shows pain score improvements and functional gains similar to what’s seen in knee OA. The challenge is that hip joints are deeper and harder to access for direct injection, making IV delivery an attractive systemic approach.
Shoulder Pain & Rotator Cuff
Rotator cuff is a standout application for MSC therapy. Multiple RCTs show significantly reduced re-tear rates and faster recovery.
What the research says
Rotator cuff injuries are one of the real success stories in MSC research. Multiple randomized controlled trials have shown that MSCs used alongside surgical repair can cut re-tear rates dramatically â some studies by as much as half. For partial tears, standalone MSC therapy has shown meaningful pain reduction and improved function, giving many patients a viable non-surgical path to recovery.
Frailty & Aging
A growing field. The landmark CRATUS trial showed improved physical function and reduced inflammation in frail elderly patients.
What the research says
The CRATUS trial (Phase I/II) is the landmark study here. It administered IV MSCs to frail elderly patients and found improvements in physical performance measures (like 6-minute walk distance), reduced inflammatory markers (TNF-alpha), and improved quality of life scores. This is one of the few areas with published data specifically on IV delivery of allogeneic (donor-derived) MSCs.
Systemic Inflammation & Wellness
MSCs are potent modulators of inflammation. The mechanism is well-established even as clinical applications continue developing.
What the research says
The anti-inflammatory mechanism of MSCs is among the most well-understood aspects of stem cell biology. MSCs secrete anti-inflammatory molecules (like IL-10, TGF-Îē) and modulate immune cell behavior. This is why MSCs show benefits across such a wide range of conditions â chronic inflammation underlies many diseases. Clinical evidence for “general wellness” is mostly derived from studies on specific conditions rather than wellness per se.
Parkinson’s Disease
Active research area with neuroprotective potential, but clinical evidence in humans is still early-stage.
What the research says
Animal studies have shown that MSCs can provide neuroprotective effects and reduce neuroinflammation in Parkinson’s models. However, human clinical trial data is very limited â mostly small case series and Phase I safety studies. The blood-brain barrier is a significant challenge for IV delivery. This is a condition where the science is hopeful but the clinical proof is still years away.
Multiple Sclerosis (MS)
Combines autoimmune and neurological benefits. More clinical data than most neuro conditions, with encouraging safety and stabilization results.
What the research says
MS sits at the intersection of autoimmune and neurological research â making it a natural fit for MSCs, which can both calm overactive immune responses and support tissue repair. Several Phase I/II trials have been conducted, including the major multicenter MESEMS trial. Results show strong safety and many patients experience stabilization or improvement in disability scores. Because MS involves the immune system attacking nerve tissue, MSCs’ dual capability makes them a uniquely promising approach.
Heart Disease & Heart Failure
One of the earliest areas of stem cell research. Large trials have been conducted but results are mixed.
What the research says
Cardiac stem cell therapy was one of the first major research areas. Hundreds of clinical trials have been registered. The results are honestly mixed: some studies show modest improvements in heart function (ejection fraction), while others show no significant difference vs. placebo. The field has also dealt with some high-profile retractions that set research back. However, MSC-specific studies tend to show more consistent safety and modest benefit.
Conditions We Currently Treat
Based on the current evidence and our clinical experience, The Stem Cell Club focuses on the conditions where MSC therapy has the strongest research support.
The information above is compiled from published clinical research and peer-reviewed literature on mesenchymal stem cell therapy. Evidence ratings reflect the volume and quality of published studies as of 2025. Individual results may vary.
Stem cell therapy is not FDA-approved for the treatment of any specific disease or condition. The Stem Cell Club provides these summaries for educational purposes to help patients make informed decisions. Always consult with a qualified healthcare provider before pursuing any treatment.